Study of ARO-ANG3 in Adults with Mixed Dyslipidemia (H-49750)

The purpose of this study is to evaluate the efficacy and safety of an investigational drug in patients with mixed dyslipidemia. Participants will receive two subcutaneous injections of drug or placebo during the 36-week study. Eligibility requirements include triglycerides 150 mg/dL or higher but less than 499 mg/dL, either LDL-C 70 mg/dL or higher or non-HDL-C 100 mg/dL or higher on statin therapy, no recent pancreatitis or major surgery, and no current diagnosis of nephrotic syndrome.